<DOC>
	<DOC>NCT00855010</DOC>
	<brief_summary>Randomized, double blind, placebo controlled trial evaluating the effect of pioglitazone on pancreatic fat content and bone turnover markers.</brief_summary>
	<brief_title>Pioglitazone on Pancreatic Steatosis and Bone Health</brief_title>
	<detailed_description />
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Fat level in the pancreas above 4% (measurement done by us with an MRI) English speaker over 21 years old contraindication to MRI anemia pregnancy or desire to conceive use of unapproved medications prior pancreatic disease use of more then 2 alcoholic drinks every day</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Pioglitazone</keyword>
	<keyword>prediabetes</keyword>
	<keyword>diabetes</keyword>
	<keyword>obesity</keyword>
	<keyword>Pancreatic fat</keyword>
</DOC>